Clinical Trials Browser

Phase 1/2 × MLN 8237 × Thoracic × Clear all

NCT01471964 2018-05-17

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Phase 1/2 Terminated

Non-small Cell Lung Cancer Metastatic

NCT01045421 2016-08-15

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Phase 1/2 Completed

273 enrolled 28 charts

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma